Wire · opportunities
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 August 2026 · Fusion42 review
Antengene has received regulatory approval in Australia to commence a Phase I clinical trial of ATG-201, a bispecific T-cell engager antibody targeting B cell-related autoimmune diseases, complementing prior approval in China and supporting their multi-regional clinical development strategy.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 25 Aug 2026 and 26 Aug 2026.
◆ ◆ The Wire takeaway
Your autoimmune disease drug can now start clinical trials in Australia, opening a critical market early. This approval lets you push global clinical validation forward alongside China without typical delays.
◆ Coverage
2 sources · first reported 25 Aug 2026 · latest 26 Aug 2026
◆ Related on Wire
◆ Topics